BACKGROUND: Our laboratory has previously shown that adoptive transfer of in vitro-expanded autologous purified polyclonal CD4(+) T cells using anti-CD3/CD28-coated beads induced antiviral responses capable of controlling SIV replication in vivo. METHODS: As CD4(+) T cells comprise several phenotypic and functional lineages, studies were carried out to optimize the in vitro culture conditions for maximal CD4(+) T-cell expansion, survival and delineate the phenotype of these expanded CD4(+) T cells to be linked to maximal clinical benefit. RESULTS AND CONCLUSIONS: The results showed that whereas anti-monkey CD3gamma/epsilon was able to induce T-cell proliferation and expansion in combination with antibodies against multiple co-stimulatory molecules, monkey CD3epsilon cross reacting antibodies failed to induce proliferation of macaque CD4(+) T cells. Among co-stimulatory signals, anti-CD28 stimulation was consistently superior to anti-4-1BB, CD27 or ICOS while the use of anti-CD154 failed to deliver a detectable proliferation signal. Increasing the relative anti-CD28 co-stimulatory signal relative to anti-CD3 provided a modest enhancement of expansion. Additional strategies for optimization included attempts to neutralize free radicals, enhancement of glucose uptake by T cells or addition of T-cell stimulatory cytokines. However, none of these strategies provided any detectable proliferative advantage. Addition of 10 autologous irradiated feeder cells/expanding T cell provided some enhancement of expansion; however, given the high numbers of T cell needed, this approach was deemed impractical and costly, and lower ratios of feeder to expanding T cells failed to provide such benefit. The most critical parameter for efficient expansion of purified CD4(+) T cells from multiple monkeys was the optimization of space and culture conditions at culture inception. Finally, anti-CD3/28-expanded CD4(+) T cells uniformly exhibited a central memory phenotype, absence of CCR5 expression, marked CXCR4 expression in vitro, low levels of caspase 3 but also of Bcl-2 expression.
BACKGROUND: Our laboratory has previously shown that adoptive transfer of in vitro-expanded autologous purified polyclonal CD4(+) T cells using anti-CD3/CD28-coated beads induced antiviral responses capable of controlling SIV replication in vivo. METHODS: As CD4(+) T cells comprise several phenotypic and functional lineages, studies were carried out to optimize the in vitro culture conditions for maximal CD4(+) T-cell expansion, survival and delineate the phenotype of these expanded CD4(+) T cells to be linked to maximal clinical benefit. RESULTS AND CONCLUSIONS: The results showed that whereas anti-monkey CD3gamma/epsilon was able to induce T-cell proliferation and expansion in combination with antibodies against multiple co-stimulatory molecules, monkey CD3epsilon cross reacting antibodies failed to induce proliferation of macaque CD4(+) T cells. Among co-stimulatory signals, anti-CD28 stimulation was consistently superior to anti-4-1BB, CD27 or ICOS while the use of anti-CD154 failed to deliver a detectable proliferation signal. Increasing the relative anti-CD28 co-stimulatory signal relative to anti-CD3 provided a modest enhancement of expansion. Additional strategies for optimization included attempts to neutralize free radicals, enhancement of glucose uptake by T cells or addition of T-cell stimulatory cytokines. However, none of these strategies provided any detectable proliferative advantage. Addition of 10 autologous irradiated feeder cells/expanding T cell provided some enhancement of expansion; however, given the high numbers of T cell needed, this approach was deemed impractical and costly, and lower ratios of feeder to expanding T cells failed to provide such benefit. The most critical parameter for efficient expansion of purified CD4(+) T cells from multiple monkeys was the optimization of space and culture conditions at culture inception. Finally, anti-CD3/28-expanded CD4(+) T cells uniformly exhibited a central memory phenotype, absence of CCR5 expression, marked CXCR4 expression in vitro, low levels of caspase 3 but also of Bcl-2 expression.
Authors: R C Zahn; F G Hermann; E-Y Kim; M D Rett; S M Wolinsky; R P Johnson; F Villinger; D von Laer; J E Schmitz Journal: Gene Ther Date: 2008-05-01 Impact factor: 5.250
Authors: Craig B Wilen; Jianbin Wang; John C Tilton; Jeffrey C Miller; Kenneth A Kim; Edward J Rebar; Scott A Sherrill-Mix; Sean C Patro; Anthony J Secreto; Andrea P O Jordan; Gary Lee; Joshua Kahn; Pyone P Aye; Bruce A Bunnell; Andrew A Lackner; James A Hoxie; Gwenn A Danet-Desnoyers; Frederic D Bushman; James L Riley; Philip D Gregory; Carl H June; Michael C Holmes; Robert W Doms Journal: PLoS Pathog Date: 2011-04-14 Impact factor: 6.823
Authors: Mirko Paiardini; Barbara Cervasi; Elane Reyes-Aviles; Luca Micci; Alexandra M Ortiz; Ann Chahroudi; Carol Vinton; Shari N Gordon; Steven E Bosinger; Nicholas Francella; Paul L Hallberg; Elizabeth Cramer; Timothy Schlub; Ming Liang Chan; Nadeene E Riddick; Ronald G Collman; Cristian Apetrei; Ivona Pandrea; James Else; Jan Munch; Frank Kirchhoff; Miles P Davenport; Jason M Brenchley; Guido Silvestri Journal: Nat Med Date: 2011-06-26 Impact factor: 53.440
Authors: Gavin I Ellis; Kimberly E Coker; Delaine W Winn; Mosha Z Deng; Divanshu Shukla; Vijay Bhoj; Michael C Milone; Wei Wang; Chengyang Liu; Ali Naji; Raimon Duran-Struuck; James L Riley Journal: Cell Rep Med Date: 2022-05-11